Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer.
10.3760/cma.j.cn112152-20220412-00251
- Collective Name:China Anti-cancer Association Tumor Drug Clinical Research Committee;;Breast Cancer Expert Committee, National Tumor Quality Control Center;;Tumor Pathology Committee of China Anti-cancer Association;;Boao Institute of Oncology Innovation
- Publication Type:Journal Article
- Keywords:
AKT inhibitor;
Breast neoplasms;
Hormone receptor;
PI3K inhibitor;
mTOR inhibitor
- MeSH:
Breast Neoplasms/metabolism*;
Consensus;
Everolimus/therapeutic use*;
Female;
Humans;
MTOR Inhibitors;
Phosphatidylinositol 3-Kinase/metabolism*;
Phosphatidylinositol 3-Kinases/metabolism*;
Phosphoinositide-3 Kinase Inhibitors;
Proto-Oncogene Proteins c-akt/metabolism*;
Sirolimus/therapeutic use*;
TOR Serine-Threonine Kinases/metabolism*
- From:
Chinese Journal of Oncology
2022;44(7):673-692
- CountryChina
- Language:Chinese
-
Abstract:
Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays an important role in the development of breast cancer and are closely associated with the resistance to endocrine therapy in advanced breast cancer. Therefore, anti-cancer treatment targeting key molecules in this signaling pathway has become research hot-spot in recent years. Randomized clinical trials have demonstrated that PI3K/AKT/mTOR inhibitors bring significant clinical benefit to patients with advanced breast cancer, especially to those with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER) 2-negative advanced breast cancer. Alpelisib, a PI3K inhibitor, and everolimus, an mTOR inhibitor, have been approved by Food and Drug Administration. Based on their high efficacy and relatively good safety profile, expanded indication of everolimus in breast cancer have been approved by National Medical Products Administration. Alpelisib is expected to be approved in China in the near future. The members of the consensus expert panel reached this consensus to comprehensively define the role of PI3K/AKT/mTOR signaling pathway in breast cancer, efficacy and clinical applications of PI3K/AKT/mTOR inhibitors, management of adverse reactions, and PIK3CA mutation detection, in order to promote the understanding of PI3K/AKT/mTOR inhibitors for Chinese oncologists, improve clinical decision-making, and prolong the survival of target patient population.
